文献速递生殖医学

低抗苗勒管激素水平与正常抗苗勒管激素水平不孕女性口服和注射促排卵后的妊娠结局比较

Pregnancy outcomes after oral and injectable ovulation induction in women with infertility with a low antimüllerian hormone level compared with those with a normal antimüllerian hormone level.
PubMed 文献 · Fertil Steril · 2022-11-12

本回顾性队列研究纳入2015至2019年在本中心完成至少1个药物促排卵/宫腔内人工授精周期的患者,按抗苗勒管激素(AMH)水平分为低AMH组(<1.0 ng/mL)和正常AMH组(≥1.0 ng/mL)。口服抗雌激素治疗时,各年龄组两组的持续妊娠率相当;注射促性腺激素治疗时,低AMH组在<35岁和35-40岁年龄段的持续妊娠率低于正常AMH组,但多胎妊娠比例也较低。

要点

  • 口服抗雌激素促排卵/宫腔内人工授精时,低AMH组各年龄段的持续妊娠率与正常AMH组相当。
  • 注射促性腺激素时,低AMH组<35岁和35-40岁的持续妊娠率低于正常AMH组,>40岁两组相当。
  • 注射促性腺激素时,正常AMH组的多胎妊娠比例高于低AMH组(31.1% vs 18.6%)。

核心结论

  • 与正常卵巢储备相比,低卵巢储备患者采用口服抗雌激素行促排卵/宫腔内人工授精,各年龄组的卵泡发育和持续妊娠率相当。
  • 低卵巢储备患者采用促性腺激素行促排卵/宫腔内人工授精时,多卵泡募集可能性较低,导致<35岁和35-40岁患者的持续妊娠率显著降低,但多胎妊娠也减少。
  • 低卵巢储备患者口服抗雌激素周期的持续妊娠率为8.7%,注射促性腺激素周期为8.1%,与一般不孕人群的预期率相当。

研究设计与样本

  • 回顾性队列研究,设置于学术中心。
  • 纳入2015至2019年在本中心完成至少1个药物促排卵/宫腔内人工授精周期的患者。
  • AMH水平在治疗开始前12个月内测量;低AMH组为AMH<1.0 ng/mL,正常AMH组为AMH≥1.0 ng/mL。
  • 纳入初次周期开始日期后1年内所有后续药物促排卵/宫腔内人工授精周期,最多至第3个完成周期或直至记录到持续妊娠。
  • 共3,122例患者完成5,539个口服抗雌激素周期,1,060例完成1,630个注射促性腺激素周期;按年龄(<35、35-40、>40岁)分层,采用年龄调整的泊松模型以风险比量化两组与二分类终点的关系。

主要发现

  • 口服抗雌激素治疗时,低AMH组与正常AMH组的每周期持续妊娠率分别为:<35岁15.4% vs 14.9%,35-40岁10.0% vs 11.0%,>40岁2.8% vs 3.3%。
  • 注射促性腺激素治疗时,低AMH组与正常AMH组的持续妊娠率分别为:<35岁12.1% vs 23.5%(RR 0.52,95%CI 0.28-0.97),35-40岁12.5% vs 18.5%(RR 0.70,95%CI 0.49-0.99),>40岁3.0% vs 4.0%(RR 0.86,95%CI 0.31-2.35)。
  • 口服抗雌激素治疗时,低AMH组与正常AMH组的多胎妊娠比例分别为13.1% vs 10.8%。
  • 注射促性腺激素治疗时,正常AMH组的多胎妊娠比例高于低AMH组(31.1% vs 18.6%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the ongoing pregnancy rate among patients with infertility with a low antimüllerian (AMH) level compared with those with a normal AMH level after oral and injectable ovulation induction (OI)/intrauterine insemination (IUI). DESIGN: Retrospective cohort. SETTING: Academic center. PATIENT(S): Patients completing ≥1 medicated OI/IUI cycle at our center between 2015 and 2019 were included. The AMH levels were measured within 12 months of treatment initiation. The cohort was stratified into low AMH (AMH level, <1.0 ng/mL) and normal AMH (AMH level, ≥1.0 ng/mL) groups. All subsequent medicated OI/IUI cycles occurring within 1 year of initial cycle start date were included up to the third completed cycle or until an ongoing pregnancy was recorded. Patients were stratified by age (<35, 35-40, and >40 years), and the relationship between the low and normal AMH groups and each binary endpoint were quantified as risk ratios using the age-adjusted Poisson models. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Ongoing pregnancy. RESULT(S): A total of 3,122 patients completed 5,539 oral antiestrogen cycles, and 1,060 completed 1,630 injectable gonadotropin cycles. For oral antiestrogen treatment, pregnancy outcomes, including ongoing pregnancy rate per cycle, for patients with a low AMH level were comparable with those for patients with a normal AMH level (<35 years, 15.4% vs. 14.9%; 35-40 years, 10.0% vs. 11.0%; and >40 years, 2.8% vs. 3.3%). For injectable gonadotropin treatment, the ongoing pregnancy rate was lower in the low AMH group than in the normal AMH group for the ages of <35 (12.1% vs. 23.5%; relative risk [RR], 0.52 [95% confidence interval {CI}, 0.28-0.97]) and 35-40 (12.5% vs. 18.5%; RR, 0.70 [95% CI, 0.49-0.99]) years but comparable with that for patients aged >40 years (3.0% vs. 4.0%; RR, 0.86 [95% CI, 0.31-2.35]). The proportion of multifetal gestations was similar between the low and normal AMH groups treated with oral antiestrogens (13.1% vs. 10.8%); however, for injectable gonadotropin treatment, patients with a normal AMH level had a higher proportion of multifetal gestations (18.6% vs. 31.1%). CONCLUSION(S): Compared with normal ovarian reserve, treatment with oral antiestrogens for OI/IUI for patients with low ovarian reserve results in comparable follicular development and ongoing pregnancy rates for all age groups. When patients with low ovarian reserve are treated with gonadotropins for OI/IUI, multifollicular recruitment is less likely resulting in a significantly decreased ongoing pregnancy rate for patients aged <35 and 35-40 years but also a decrease in multifetal gestations. Overall, the ongoing pregnancy rates of 8.7% per oral antiestrogen cycle and 8.1% per injectable gonadotropin cycle in patients with low ovarian reserve are comparable with the expected rates in the general infertility population.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Romanski PA, Bortoletto P, Malmsten JE, et al. Pregnancy outcomes after oral and injectable ovulation induction in women with infertility with a low antimüllerian hormone level compared with those with a normal antimüllerian hormone level. Fertil Steril. 2022. PMID: 36379757. doi:10.1016/j.fertnstert.2022.09.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。